Skip to content
naulon
Not checkedNot checked for notices yet.

Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report

Angela L. Liang, Payam Katebi Kashi, Mark Hopkins and 4 more

Gynecologic Oncology Reports · 2021

doi:10.1016/j.gore.2021.100877 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

•A subset of patients with uterine carcinosarcoma will have ER/PR positive disease.•Hormone receptor expression may serve as a therapeutic target in high-grade endometrial tumors.•Hormonal therapy and SBRT may have benefit in the management of recurrent uterine carcinosarcoma.

Abstract licence: CC BY-NC-ND

References21

    21 more references, whose wording the paper’s licence keeps private.

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.